Seer Announces Publication of Seminal Study Demonstrating the Power of Engineered Nano-Bio Interactions to Enable Deep Access to the Proteome
August 23 2022 - 8:00AM
Seer, Inc. (Nasdaq: SEER) today announced the publication of a
study demonstrating the performance of the technology underlying
the Proteograph™ Product Suite for deep, unbiased, precise,
scalable proteomics. The paper, entitled “Enhanced competition at
the nano-bio interface enables comprehensive characterization of
protein corona dynamics and deep coverage of proteomes” was
published in Advanced Materials on August 20, 2022.
This study combines state-of-the-art proteomics methods,
nanoengineering, and machine learning to deeply dissect the
nano-bio interface for highly parallel sampling of proteins. The
optimization of nano-bio interactions was shown to drive protein
corona diversity and provide access to thousands of under-sampled
proteins, which could enable the discovery of novel biomarkers and
biological insights. By deeply understanding the mechanisms of
protein corona formation, nanoparticles can be engineered, and
assays developed, for highly reproducible deep unbiased proteomics
at scale.
“The publication of this paper in Advanced Materials highlights
some of the ongoing innovations we are building into our products,
which enable deep interrogation of the proteome at the peptide and
amino acid level,” said Omid Farokhzad, Chief Executive Officer,
and Chair of Seer. “This paper significantly expands the field’s
understanding of nano-bio interactions, which we leverage to
develop reproducible and scalable solutions for deep, unbiased
proteomics. Our Proteograph Product Suite is being adopted by
customers around the world to conduct first-of-their kind studies
that explore the proteome at a depth, resolution and scale that was
not possible previously.”
Seer’s Proteograph Product Suite enables proteomics studies with
an unprecedented combination of speed, scale, depth, and breadth of
data. Seer’s proprietary engineered nanoparticles deliver
reproducible performance across samples, labs, and experiments,
providing peptide level information that is key to identifying
protein variants. The accompanying Proteograph Analysis Suite
offers cloud-scalable software for proteomic data analysis,
visualization, and generation of biological insights. The
Proteograph Product Suite makes it easy to add unbiased, deep,
rapid proteomics studies at scale to any lab.
About Seer
Seer™ is a life sciences company developing transformative
products that open a new gateway to the proteome. Seer’s
Proteograph Product Suite is an integrated solution that includes
proprietary engineered nanoparticles, consumables, automation
instrumentation and software to perform deep, unbiased proteomic
analysis at scale in a matter of hours. Seer designed the
Proteograph workflow to be efficient and easy to use, leveraging
widely adopted laboratory instrumentation to provide a
decentralized solution that can be incorporated by nearly any lab.
Seer’s Proteograph Product Suite is for research use only and is
not intended for diagnostic procedures. For more information,
please visit www.seer.bio.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Such forward-looking statements are based on
Seer’s beliefs and assumptions and on information currently
available to it on the date of this press release. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause Seer’s actual results, performance, or
achievements to be materially different from those expressed or
implied by the forward-looking statements. These statements include
but are not limited to statements regarding access to thousands of
under-sampled proteins, discovery of novel biomarkers and
biological insights, deep interrogation of the proteome at the
peptide and amino acid level, the ability of the Proteograph
Product Suite to enable proteomics studies with an unprecedented
combination of speed, scale, depth, and breadth of data. These and
other risks are described more fully in Seer’s filings with the
Securities and Exchange Commission (“SEC”) and other documents that
Seer subsequently files with the SEC from time to time. Except to
the extent required by law, Seer undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
Media Inquiries:Karen Possematopr@seer.bio
Investor Inquiries:Carrie
Mendivilinvestor@seer.bio
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jul 2023 to Jul 2024